A Phase II Study of Basmisanil in Children and Adolescents With Dup15q Syndrome
The primary goal of this Phase 2 clinical trial is to determine the effects of a selective negative allosteric modulator (NAM) of GABAA α5 receptor, Basmisanil (NTX-1511), on brain wave (EEG) characteristics in children and adolescents with Dup15q syndrome. The main questions this trial aims to answer are: * How does NTX-1511 affect brain waves (as measured by EEG) in subjects with Dup15q syndrome? * Does NTX-1511 impact other developmental features of subjects with Dup15q syndrome? Researchers will compare the effects of NTX-1511 with matching placebo (look-alike granules that contain no drug). Participants will: * Take NTX-1511 or matching placebo 3 times every day for 12 weeks * Visit the clinic 7 times over the course of 23 weeks
Parent, caregiver, or legally authorized representatives has provided written in... [+3]
Pathogenic or likely pathogenic genomic variant outside of the BP2-BP3 segment.... [+3]